Waters and DAISO Sign Marketing Agreement for Bulk Process Chromatography Media
News Feb 18, 2010
Waters Corporation and DAISO CO., LTD. have jointly announced that they are entering into a collaborative agreement to globally market and supply DAISOGEL™ bulk packing materials for process chromatography.
The combined purification expertise of both organizations will aid pharmaceutical and biopharmaceutical companies as they move from lab-scale purifications into pilot plant and process-scale manufacturing.
To simplify scaling-up purification methods, DAISOGEL™ columns are packed using Waters patented Optimum Bed Density (OBD™) Technology. OBD Technology enables analytical column performance and industry best lifetime in larger preparative columns. Scientists will save time by eliminating the need for subsequent method redevelopment as they increase in scale.
As drug manufacturers invest significant amounts of money to manufacture new drug substances, they need solid commitments from established high quality process bulk suppliers with a long track record for synthesizing chromatographic media for drug purification processes.
DAISO’s comprehensive quality control system is based on ISO 9001 and has met the quality requirements of global pharmaceutical companies. DAISO also has a DMF (Drug Master File) on file with the U.S Food and Drug Administration (FDA) for the DAISOGEL™ packing materials.
Whether they need gram quantity amounts or hundreds of kilograms of bulk media, contract manufacturing organizations, innovator pharmaceutical, biopharmaceutical, natural product, and generic pharmaceutical laboratories can find the media they need in the right quantity and quality from Waters Corporation.
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE